Shernan Holtan, MD, is an associate professor of Medicine at the University of Minnesota and Medical Director of the Clinical Trials Office - Cell, Gene, and Immunotherapy Program for the Masonic Cancer Center. In her clinical role, she focuses on enhancing the safety and efficacy of allogeneic hematopoietic cell transplants for malignant and non-malignant diseases. In her research role, she is studying how enhancements to tissue regeneration, through medications and strength-based exercise, can help improve outcomes of allogeneic hematopoietic cell transplantation. Her research funded by Regenerative Medicine Minnesota led to a new orphan drug designation from the FDA for repurposing an inexpensive and safe drug to treat acute graft-versus-host disease.
Shernan Holtan, MD